倪千喜,蔡奕龙,王 亮.中央型非小细胞肺癌肿瘤体积与位置对调强放射治疗靶区剂量的影响[J].肿瘤学杂志,2019,25(7):634-636. |
中央型非小细胞肺癌肿瘤体积与位置对调强放射治疗靶区剂量的影响 |
Effect of Tumor Volume and Site on Target Dose in Intensity-Modulated Radiotherapy for Central Non-small Cell Lung Cancer |
投稿时间:2018-10-11 |
DOI:10.11735/j.issn.1671-170X.2019.07.B009 |
|
|
中文关键词: 非小细胞肺癌 调强放射治疗 肿瘤体积 肿瘤位置 靶区剂量 |
英文关键词:non-small cell lung cancer intensity-modulated radiotheray tumor volume tumor site target dose |
基金项目:湖南省自然科学基金青年基金项目(2017JJ3196) |
|
摘要点击次数: 2183 |
全文下载次数: 485 |
中文摘要: |
摘 要: [目的] 评价中央型非小细胞肺癌(NSCLC)调强放疗中肿瘤体积、位置与靶区剂量的相关性。[方法] 回顾性分析2017年1月至12月接受调强放疗的中央型NSCLC患者60例,计划靶区(PTV)处方剂量为60~66Gy,30次,2.0~2.2Gy/次。分析PTV体积与全肺组织的体积百分比(VPTV/VLung)、PTV的D95、PTV离脊髓的最小距离,利用回归模型进行曲线拟合分析肿瘤体积与位置对靶区剂量的相关性。[结果] VPTV/VLung小于10%,PTV离脊髓的最小距离大于5mm时,PTV的D95大于60Gy。PTV离脊髓的最小距离大于20mm时,PTV的D95大于66Gy;VPTV/VLung大于30%,PTV离脊髓的最小距离小于10mm时,PTV的D95小于55Gy。[结论] 中央型NSCLC患者调强放射治疗中,VPTV/VLung、PTV的D95、PTV离脊髓的最小距离三者之间存在相关性。肿瘤体积与位置是靶区能否达到处方剂量要求的重要影响因素。 |
英文摘要: |
Abstract:[Objective] To investigate the effect of tumor volume and site on target dose in intensity-modulated radiotherapy(IMRT) for central non-small cell lung cancer(NSCLC). [Methods] Sixty patients with central NSCLC undergoing IMRT from January to December 2017 were retrospectively analyzed. The prescribed dose of planning target volume(PTV) was 60~66Gy,30 fractions,2~2.2Gy/fraction. The volume percent of the PTV and total lung(VPTV/VLung),the dose of 95% volume of PTV(D95),and the minimum distance from spinal cord to PTV were analyzed. The correlation between the tumor volume,site and target dose was analyzed with regression model curve. [Results] When the VPTV/VLung was <10% and the minimum distance to the spinal cord was >5 mm,the D95 of PTV was >60Gy. The minimum distance to spinal cord was>20mm,the D95 of PTV was >66Gy. When the VPTV/VLung was >30% and the minimum distance to spinal cord was <10mm,the D95 of PTV was <55Gy. [Conclusion] There is a correlation between the VPTV/VLung,the D95 of PTV,and the minimum distance from spinal-cord to PTV. The volume and site of the tumor is the key factor for the prescription dose of tumor target. |
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |